GlaxoSmithKline Pharmaceuticals
- Advice
- Hold
Glaxosmithkline Pharmaceuticals Performance
Day Range
- Low 1,669.95
- High 1,708.00
52 Week Range
- Low 1,227.00
- High 1,727.00
- Open Price1,670.00
- Previous Close1,657.10
- Volume215618
Start SIP in GlaxoSmithKline Pharmaceuticals
Start SIPGlaxosmithkline Pharmaceuticals Investment Rating
-
Master Rating:
-
Glaxosmithkline Pharms. has an operating revenue of Rs. 3,308.40 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 26% is great, ROE of 35% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 18% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 2% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 84 which is a GOOD score indicating consistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Indicator | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
---|---|---|---|---|---|---|---|
Oper Rev Qtr Cr | 953 | 738 | 782 | 799 | 906 | 729 | 792 |
Operating Expenses Qtr Cr | 667 | 597 | 615 | 571 | 649 | 582 | 619 |
Operating Profit Qtr Cr | 287 | 141 | 167 | 228 | 257 | 148 | 173 |
Depreciation Qtr Cr | 18 | 16 | 17 | 16 | 16 | 16 | 15 |
Interest Qtr Cr | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
Tax Qtr Cr | 81 | 48 | 56 | 60 | 69 | 44 | 262 |
Net Profit Qtr Cr | 216 | 131 | 131 | 164 | 194 | 119 | 1,218 |
Glaxosmithkline Pharmaceuticals Technicals
EMA & SMA

- Bullish Moving Average
- ___
- 16
- Bearish Moving Average
- ___
- 0
- 20 Day
- ₹1,591.13
- 50 Day
- ₹1,535.75
- 100 Day
- ₹1,488.82
- 200 Day
- ₹1,443.36
- 20 Day
- ₹1,561.96
- 50 Day
- ₹1,531.48
- 100 Day
- ₹1,479.28
- 200 Day
- ₹1,396.05
Glaxosmithkline Pharmaceuticals Resistance and Support
Resistance | |
---|---|
First Resistance | 1,700.78 |
Second Resistance | 1,723.42 |
Third Resistance | 1,738.83 |
RSI | 68.94 |
MFI | 78.81 |
MACD Single Line | 40.09 |
MACD | 50.42 |
Support | |
---|---|
First Resistance | 1,662.73 |
Second Resistance | 1,647.32 |
Third Resistance | 1,624.68 |
Glaxosmithkline Pharmaceuticals Delivery and Volume
Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
---|---|---|---|
Day | 222,103 | 13,905,869 | 62.61 |
Week | 206,419 | 12,562,660 | 60.86 |
1 Month | 222,897 | 14,071,494 | 63.13 |
6 Month | 107,714 | 7,042,354 | 65.38 |
Glaxosmithkline Pharmaceuticals Result Highlights
GlaxoSmithKline Pharmaceuticals Synopsis
NSE-Medical-Diversified
Glaxosmithkline Phar is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 3216.34 Cr. and Equity Capital is Rs. 169.41 Cr. for the Year ended 31/03/2023. GlaxoSmithKline Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 13/11/1924 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1924PLC001151 and registration number is 001151.Market Cap | 28,429 |
Sales | 3,273 |
Shares in Float | 4.24 |
No of funds | 196 |
Yield | 1.91 |
Book Value | 16.22 |
U/D Vol ratio | 1.3 |
LTDebt / Equity | |
Alpha | 0.08 |
Beta | 0.34 |
GlaxoSmithKline Pharmaceuticals
Owner Name | Sep-23 | Jun-23 | Mar-23 | Dec-22 |
---|---|---|---|---|
Promoters | 75% | 75% | 75% | 75% |
Mutual Funds | 4.81% | 4.25% | 3.96% | 4.12% |
Insurance Companies | 5.15% | 5.97% | 6.29% | 6.1% |
Foreign Portfolio Investors | 2.5% | 2.41% | 2.28% | 2.28% |
Financial Institutions/ Banks | 0.01% | 0.01% | 0.01% | 0.01% |
Individual Investors | 10.62% | 10.57% | 10.54% | 10.56% |
Others | 1.91% | 1.79% | 1.92% | 1.93% |
GlaxoSmithKline Pharmaceuticals Management
Name | Designation |
---|---|
Ms. R S Karnad | Chairperson |
Mr. B Akshikar | Managing Director |
Dr.(Ms.) S Maheshwari | Director |
Mr. S Williams | Director |
Mr. P V Bhide | Director |
Mr. A N Roy | Director |
Mr. D Sundaram | Director |
Mr. M Anand | Director |
Mr. J Chandy | Director |
Glaxosmithkline Pharmaceuticals Forecast
Price Estimates
Glaxosmithkline Pharmaceuticals Corporate Action
Date | Purpose | Remarks |
---|---|---|
2023-11-09 | Quarterly Results | |
2023-07-26 | Quarterly Results | |
2023-05-17 | Audited Results & Final Dividend | |
2023-02-07 | Quarterly Results | |
2022-11-11 | Quarterly Results |
Date | Purpose | Remarks |
---|---|---|
2023-06-30 | FINAL | Rs.32.00 per share(320%)Final Dividend |
2022-07-08 | FINAL | Rs.30.00 per share(300%)Dividend |
2022-07-08 | SPECIAL | Rs.60.00 per share(600%)Special Dividend |
2021-07-20 | FINAL | Rs.30.00 per share(300%)Dividend |
GlaxoSmithKline Pharmaceuticals FAQs
What is Share Price of GlaxoSmithKline Pharmaceuticals ?
GlaxoSmithKline Pharmaceuticals share price is ₹1,678 As on 02 December, 2023 | 07:55
What is the Market Cap of GlaxoSmithKline Pharmaceuticals ?
The Market Cap of GlaxoSmithKline Pharmaceuticals is ₹28428.9 Cr As on 02 December, 2023 | 07:55
What is the P/E ratio of GlaxoSmithKline Pharmaceuticals ?
The P/E ratio of GlaxoSmithKline Pharmaceuticals is 43.9 As on 02 December, 2023 | 07:55
What is the PB ratio of GlaxoSmithKline Pharmaceuticals ?
The PB ratio of GlaxoSmithKline Pharmaceuticals is 16.3 As on 02 December, 2023 | 07:55